Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants
Accelerated Approval Adds Another Alzheimer’s Study To Global Pipeline
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
